Skip to main content
Premium Trial:

Request an Annual Quote

New Products: CTGT Adds High-density Targeted Array Testing for 10 Disorders

Premium

Connective Tissue Gene Tests this week introduced high-density targeted array deletion/duplication testing for 10 disorders, adding to 164 disorders for which it already tests.

CTGT now offers array-based testing for the following:

acromesomelic dysplasia, Maroteaux type, an autosomal recessive skeletal dysplasia caused by loss-of-function mutations in the natriuretic peptide receptor B gene;

arterial calcification, generalized, of infancy, 1, an autosomal recessive disorder characterized by calcification of arteries caused by mutations in the ectonucleotide pyrophosphatase/phosphodiesterase 1 gene;

brittle cornea syndrome 1 and 2, autosomal recessive disorders caused by mutations in the zinc finger 469 gene and PR domain-containing protein 5 genes, respectively;

cranioectodermal dysplasia 2, an autosomal recessive ciliopathy characterized by sagittal craniosynostosis, skeletal, facial, and ectodermal abnormalities caused by mutations in at least two genes, WDR35 and IFT122;

musculocontractural type Ehlers-Danlos syndrome, an autosomal recessive variant of Ehlers-Danlos syndrome caused by mutations in the carbohydrate sulfotransferase 14 gene;

exostoses, multiple, types I and II, autosomal dominant disorders characterized by multiple osteochondromas , benign, cartilage-capped bone tumors, caused by mutations in two genes, exostosin 1 and exostosin 2;

hypophosphatemic rickets, autosomal dominant, a disorder characterized by renal phosphate wasting caused by mutations in the fibroblast growth factor 23 gene;

short rib-polydactyly syndromes, types III and V, and asphyxiating thoracic dystrophy 2 and 3, autosomal recessive osteochondrodysplasias characterized by short ribs with a narrow thorax, short long bones and polydactyly; and

three M syndrome 1, 2 and 3,, autosomal recessive disorders characterized by pre- and postnatal growth retardation caused by mutations in the CUL7, OBSL1, or CCDC8 genes.

CTGT charges $1,190 for testing a gene and an additional $590 for any second gene analyzed.

CTGT's services are offered on its High-Density Targeted Array, a custom designed Agilent Technologies G3 SurePrint microarray. The firm began offering array-based testing in 2010.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.